CompanyGraph
What stands out
- Most companies in its industry are production businesses; this one is a sense-making business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $67.87M, lower than 95% of all stocks globally
- Interpretations4 currently firing — 4
What this company is and how it runs — written from structure, not news.
What stands out
- Most companies in its industry are production businesses; this one is a sense-making business
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
50.25MGBP67.87M · vs all stocks (USD)
Revenue (TTM)
49.66MGBP67.07M · vs all stocks (USD)
Profit Margin
-12.07%vs Biotechnology peers
Beta
1.71xvs all stocks
52-Week Change
-27.00%vs all stocks
Market Capitalization
50.25MGBP67.87M · vs all stocks (USD)
Enterprise Value
51.33MGBP69.32M · vs all stocks (USD)
Forward P/E
-42.20xvs Biotechnology peers
Price to Sales (TTM)
1.01xvs Biotechnology peers
Price to Book (MRQ)
1.30xvs Biotechnology peers
Enterprise to Revenue
1.03xvs Biotechnology peers
Enterprise to EBITDA
-81.35xvs Biotechnology peers
Profit Margin
-12.07%vs Biotechnology peers
Operating Margin
-17.76%vs Biotechnology peers
Return on Assets (TTM)
-2.52%vs Biotechnology peers
Return on Equity (TTM)
-14.47%vs Biotechnology peers
Revenue (TTM)
49.66MGBP67.07M · vs all stocks (USD)
Revenue per Share (TTM)
0.0720GBPUpdated Aug 3, 2026Quarterly Revenue Growth
-16.60%vs Biotechnology peers
Gross Profit (TTM)
1.42MGBP1.92M · vs all stocks (USD)
EBITDA (TTM)
2.61MGBP3.52M · vs all stocks (USD)
Net Income (TTM)
-5.99MGBP-8.09M · vs all stocks (USD)
Operating Cash Flow (TTM)
-14.42MGBP-19.47M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-11.38MGBP-15.36M · vs all stocks (USD)
Payout Ratio
25.97%vs Biotechnology peers
Revenue
62.73MGBPFY2024 · Dec 31, 2024Operating Income
12.86MGBP17.36M · vs all stocks (USD)
Pre-tax Income
13.29MGBPFY2024 · Dec 31, 2024Income Tax Expense
2.64MGBPFY2024 · Dec 31, 2024Net Income
10.65MGBPFY2024 · Dec 31, 2024EBIT
14.24MGBPFY2024 · Dec 31, 2024EBITDA (Income Statement)
17.80MGBPFY2024 · Dec 31, 2024Selling, General & Administrative
26.13MGBPFY2024 · Dec 31, 2024Non-operating Interest Income
1.83MGBPFY2024 · Dec 31, 2024Non-operating Interest Expense
955.00KGBPFY2024 · Dec 31, 2024EPS (Basic)
0.0157GBPFY2024 · Dec 31, 2024EPS (Diluted)
0.0155GBPFY2024 · Dec 31, 2024Basic Shares Outstanding
680.37MSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
680.37MSharesFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00GBPFY2024 · Dec 31, 2024Operating Cash Flow
11.67MGBPFY2024 · Dec 31, 2024Free Cash Flow
9.26MGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
44.18MGBPFY2024 · Dec 31, 2024Starting Profit (CF Statement)
13.29MGBPFY2024 · Dec 31, 2024Stock-based Compensation
836.00KGBPFY2024 · Dec 31, 2024Other Non-cash Items
-3.82MGBPFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
1.75MGBPFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
-378.00KGBPFY2024 · Dec 31, 2024Capital Expenditures
-2.42MGBPFY2024 · Dec 31, 2024Net Intangibles (CF)
-44.00KGBPFY2024 · Dec 31, 2024Net Investing Cash Flow
-2.42MGBPFY2024 · Dec 31, 2024Common Dividends Paid
-1.36MGBPFY2024 · Dec 31, 2024Net Financing Cash Flow
-1.36MGBPFY2024 · Dec 31, 2024Shares Outstanding
687.01MSharesUpdated Aug 3, 2026Float Shares
571.16MSharesUpdated Aug 3, 2026% Held by Insiders
3.16%vs all stocks
% Held by Institutions
30.79%vs all stocks
Total Cash (MRQ)
14.30MGBP19.31M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0210GBPUpdated Aug 3, 2026Total Debt (MRQ)
14.79MGBP19.97M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3875xvs Biotechnology peers
Current Ratio (MRQ)
1.63xvs Biotechnology peers
Book Value per Share (MRQ)
0.0560GBPUpdated Aug 3, 2026Total Assets
88.89MGBP120.05M · vs all stocks (USD)
Total Current Assets
60.23MGBPFY2024 · Dec 31, 2024Total Liabilities
44.22MGBPFY2024 · Dec 31, 2024Total Non-current Assets
28.66MGBPFY2024 · Dec 31, 2024Total Non-current Liabilities
12.30MGBPFY2024 · Dec 31, 2024Total Current Liabilities
31.91MGBPFY2024 · Dec 31, 2024Cash
44.18MGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents
44.18MGBPFY2024 · Dec 31, 2024Accounts Receivable
4.47MGBPFY2024 · Dec 31, 2024Inventory
804.00KGBPFY2024 · Dec 31, 2024Accounts Payable
1.88MGBPFY2024 · Dec 31, 2024Short-term Debt
2.51MGBPFY2024 · Dec 31, 2024Long-term Debt
10.39MGBPFY2024 · Dec 31, 2024Common Stock (Book)
680.00KGBPFY2024 · Dec 31, 2024Retained Earnings
48.81MGBPFY2024 · Dec 31, 2024Total Shareholders' Equity
44.67MGBP60.33M · vs all stocks (USD)
52-Week Low
4.30GBXUpdated Aug 3, 202652-Week High
11.50GBXUpdated Aug 3, 202652-Week Change
-27.00%vs all stocks
Beta
1.71xvs all stocks
50-Day MA
7.53GBXUpdated Aug 3, 2026200-Day MA
7.11GBXUpdated Aug 3, 2026Avg 10-Day Volume
1.54MSharesUpdated Aug 3, 2026Avg 30-Day Volume
1.07MSharesUpdated Aug 3, 2026Diluted EPS (TTM)
-0.0100GBPUpdated Aug 3, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Most companies in its industry are production businesses; this one is a sense-making businessSignificant
Industry peers: 502Share on the common pattern %: 98.00
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $67.87M, lower than 95% of all stocks globallySignificant
Market cap (USD): 67,868,560.564Global P5: 269,387,740.27
Companies that share the same coordination system — how they create, deliver, or capture value.
Ixico plc
Tier 1SenseMakingApproval-Gated PipelineProductionInterface
Fusion Antibodies Ltd.
Tier 1SenseMakingApproval-Gated PipelineProduction
Evotec SE
Tier 1SenseMakingApproval-Gated PipelineInterfaceProduction
Shanghai Medicilon Inc.
Tier 1SenseMakingApproval-Gated PipelineProduction
Caris Life Sciences, Inc.
Tier 1SenseMakingApproval-Gated PipelineProductionInterface
Fortrea Holdings Inc.
Tier 2SenseMakingApproval-Gated PipelineFlowInterface
Oxford Metrics Plc
Tier 3SenseMakingRecurring-Revenue Lock-InInterfaceProduction
Celebrus Technologies Plc
Tier 3SenseMakingRecurring-Revenue Lock-InInterfaceProduction
Saltlux Inc.
Tier 3SenseMakingRecurring-Revenue Lock-InProductionInterface
Gateley Holdings plc
Tier 3SenseMakingExpertise LeverageRuleInterface
Companies that share active interpretations — structural patterns currently present in both stocks.
L&K Engineering Suzhou Co., Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesOperating Income Growing With Multi-Year Revenue GrowthUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Grade Upon Technology Corp.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesOperating Income Growing With Multi-Year Revenue GrowthUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Intsig Information Co., Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesOperating Income Growing With Multi-Year Revenue GrowthUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated